FULC — Fulcrum Therapeutics, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1680581 ·
Last close
$3.75
Market Cap
$286.43M
52W High
$15.74
52W Low
$2.83
ADV30
1,391,345
Next earnings
2026-11-16
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops small molecules to improve the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its clinical-stage product candidate is pociredir, a fetal hemoglobin inducer, which is in phase 1b clinical trial for the treatment of sickle cell disease and beta-thalassemia. The company also discovers programs for the treatment of diamond-blackfan anemia, Bone Marrow Failure Syndromes, novel fetal hemoglobin inducers, fibrotic disorders. It has licensce agreement with CAMP4 which includes certain small molecule compounds, composition of matter and method of use patent rights, and know-how to research, develop, manufacture, use, and commercialize. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -11,467,000 -10,939,000 310,811,000 116,410,000 8,784,000
Jun 2026 0 — -19,906,000 -26,179,000 323,952,000 48,466,000 13,255,000
Mar 2026 0 — -22,186,000 -18,891,000 346,770,000 50,261,000 13,467,000
Dec 2025 0 — -22,693,000 -20,334,000 366,284,000 197,533,000 17,284,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-65,777,000
Investing CF
$-96,868,000
Financing CF
$168,410,000
CapEx
$-365,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.21
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-639,348,000
Inventory
—
Receivables
$2,030,000
ST Investments
$270,374,000
EBIT TTM
$-86,643,000
Pretax Income TTM
$-84,999,000
Interest Exp TTM
—
Analysts
3

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -84,769,000 -74,880,000 366,284,000 17,284,000 349,000,000 -60,065,000
Dec 2024 80,000,000 -19,834,000 -9,725,000 260,718,000 17,684,000 243,034,000 -2,218,000
Dec 2023 2,805,000 -110,664,000 -97,335,000 257,694,000 22,501,000 235,193,000 -90,965,000
Dec 2022 6,342,000 -112,134,000 -109,871,000 226,685,000 27,743,000 198,942,000 -97,050,000

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-84,999,000
OpCashFlow TTM
—
Assets (Latest)
$323,952,000
Forward EPS
$-0.55

Max Pain — expiry 2026-12-18

max pain strike: $4.00 · spot: $3.72 · call oi: 4,378 · put oi: 360
Expected Move to 2026-12-18: ±$0.35 (9.41%) — implied range $3.37 – $4.07 · ATM straddle on $4.00 strike

Peers — same industry

TickerNameMarket CapLastDaily %
MPLT MapLight Therapeutics, Inc. $286.78M $6.57 —
VCRE Vicore Pharma Holding AB $285.02M $10.12 —
EBS Emergent BioSolutions Inc. $288.44M $5.61 —
BNTC Benitec Biopharma Inc. $284.35M $8.15 —
EVMN Evommune, Inc. $290.28M $7.02 —

News headlines (Yahoo Finance, 1h cache)

Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough?
2026-08-25 18:28 · Yahoo
Fulcrum and Slate Medicines sign merger agreement
2026-08-18 08:56 · Yahoo
Fulcrum Therapeutics & Slate Medicines Merge for Next-Generation Migraine Therapies
2026-08-17 16:11 · Yahoo
Fulcrum Therapeutics Merges With Slate in $245M Migraine Biotech Deal
2026-08-17 13:02 · Yahoo
Fulcrum Therapeutics, Slate Medicines to Combine in All-Stock Merger
2026-08-17 11:52 · Yahoo
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
2026-08-17 11:00 · Yahoo
Slate, Fulcrum to combine in reverse merger
2026-08-17 10:23 · Yahoo
Fulcrum Therapeutics (FULC) Stock Fair Value Moves Lower After Pociredir Exit
2026-06-27 20:06 · Yahoo
Fulcrum Therapeutics (FULC) Loses 51% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-06-05 13:35 · Yahoo
A Cambridge biotech had hundreds of millions in the bank — then the FDA pulled the plug on its only drug and 85% of its staff lost their jobs
2026-06-11 19:53 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.